Oncopeptides Investor Relations Material
Latest events
Q4 2024
Oncopeptides
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Oncopeptides
Access all reports
Oncopeptides AB, a biotech company, focuses on the development of therapies for patients with cancer. The company's lead drug candidate is melflufen, which has received orphan drug designation from the European Commission, as well as from the FDA for the treatment of multiple myeloma. Its product pipeline also comprises peptide-drug conjugates that are in preclinical stage development for hematological malignancies and solid tumors. The company is based in Stockholm, Sweden
Key slides for Oncopeptides
Q2 2024
Oncopeptides
Q4 2024
Oncopeptides
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
ONCO
Country
🇸🇪 Sweden